Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B-cell acute lymphoblastic leukemia.
[Blood Advances]
7992332
{7992332:5XGDK8BI}
apa
50
1
166249
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/